Mylan / Pfizer Upjohn merger

29/7/2019

Merger

Status:

Announced

Date:

29/7/2019

Overview:

American pharmaceutical company Pfizer has announced that its off-patent branded drugs business, Pfizer Upjohn, will be merged with Dutch drug-maker Mylan.
The move brings Upjohn products such as Viagra and Lipitor together with items such as Mylan’s EpiPen. The strategy is a part of Pfizer's effort to split its business into three parts - innovative medicines, lower margin off-patent drugs facing generic competition and consumer healthcare.
The combined company is expected to have a revenue of $19 billion to $20 billion in 2020.

Prin Shasiharan - Researcher

Jurisdictions:

United States
Netherlands

Deal type:

Merger

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firms:

Cravath Swaine & Moore

Party: Mylan (Merger party)

Lawyers: Aaron Gruber, Mark Greene, Thomas Dunn

De Brauw Blackstone Westbroek

Party: Pfizer (Merger party)

Lawyer: Paul Cronheim (retired)

NautaDutilh

Party: Mylan (Merger party)

Lawyer: Paul van der Bijl

Wachtell Lipton Rosen & Katz

Party: Pfizer (Merger party)

Lawyers: Edward Herlihy, Gordon Moodie

Willkie Farr & Gallagher

Party: Centerview Partners (Financial adviser)

Party: PJT Partners (Financial adviser)

Lawyers: Laura Delanoy, Steven Seidman

Related deals